Related Experiment Video

Updated: Jun 26, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation

Jing-Ruey J Yeh1, Kathleen M Munson, Kamaleldin E Elagib

  • 1Developmental Biology Laboratory, Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA.

Nature Chemical Biology
|January 28, 2009
PubMed

Insights

Targeting oncogene AML1-ETO in leukemia may improve stem cell properties. Researchers identified COX-2 and beta-catenin pathways as key modifiers, offering new therapeutic avenues for leukemia stem cells.

Area of Science:

  • Hematology
  • Oncology
  • Developmental Biology

Background:

  • Targeting oncogene-driven processes in hematopoietic stem cells is a promising strategy for leukemia treatment.
  • Understanding the molecular mechanisms of oncogene function in stem cell differentiation is crucial for developing novel therapies.

Purpose of the Study:

  • To investigate the role of the oncogene AML1-ETO in hematopoietic progenitor cell differentiation.
  • To identify novel pathways and modifiers that regulate AML1-ETO function in leukemic stem cells.

Main Methods:

  • Development of a zebrafish in vivo hematopoietic differentiation assay to model AML1-ETO activity.
  • Screening for genetic modifiers of AML1-ETO-mediated hematopoietic dysregulation.

Main Results:

  • The study successfully established a zebrafish model for studying AML1-ETO function.
  • Unexpected roles for cyclooxygenase-2 (COX-2) and beta-catenin-dependent pathways in AML1-ETO function were uncovered.
  • These pathways significantly modify AML1-ETO-driven hematopoietic dysregulation.

Conclusions:

  • Inhibiting oncogene effects on hematopoietic stem cell differentiation may enhance current leukemia treatments.
  • The identified COX-2 and beta-catenin pathways represent potential therapeutic targets for leukemia stem cells.
  • This research provides a foundation for developing novel strategies to target oncogene function in leukemia.

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...